Allogene Therapeutics, Inc. Banner Image

Allogene Therapeutics, Inc. has reached its limit for free report views

Work for Allogene Therapeutics, Inc.? Upgrade Your Profile and unlock all your annual reports.

Allogene Therapeutics, Inc.

  • Ticker ALLO
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Allogene Therapeutics, Inc. Logo Image
  • 201-500 Employees
  • Based in South San Francisco, California
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of deliveringMore readily available cell therapy on-demand, more reliably, and at greater scale to more patients.
Allogene Therapeutics, Inc.

Most Recent Annual Report

Allogene Therapeutics, Inc.
MOST RECENT 2021 Annual Report and Form 10K

Report Locked. Allogene Therapeutics, Inc. has reached its limit for free report views.

Older/Archived Annual Reports